Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1699968

registered interest
date	12/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pharmacy: Finance
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment she has made of the potential impact of medication costs on community pharmacies.
tabling member constituency	Gosport
tabling member printed	Dame Caroline Dinenage
uin	20988
answer	answer is ministerial correction date of answer 19/04/2024 answer text <p>Through the medicine margin survey, the Department assesses whether the reimbursement arrangements pay pharmacy contractors as agreed as part of the community pharmacy contractual framework (CPCF). The medicine margin survey considers what pharmacies paid for medicines by looking at their invoices compared to the amount reimbursed by the National Health Service. Where the survey finds that they have been underpaid, we increase the pharmacy contractors’ payments, and where they have been overpaid, we decrease payments.</p><p>Furthermore, where pharmacies cannot purchase products at or below the Drug Tariff NHS reimbursement price, Community Pharmacy England can request that the Department reassesses the reimbursement price. If a new reimbursement price is issued, this is known as a concessionary price.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20979 question first answered 19/04/2024 09:54:36 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4008 label Biography information for Dame Caroline Dinenage

1699969

registered interest
date	12/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pharmacy: Finance
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether she plans to increase core community pharmacy funding.
tabling member constituency	Gosport
tabling member printed	Dame Caroline Dinenage
uin	20989
answer	answer is ministerial correction date of answer 18/04/2024 answer text <p>As part of the Community Pharmacy Contractual Framework five-year deal, we committed £2.6 billion every year to community pharmacy, and agreed not to recover £212 million in over delivered fees and margin from community pharmacies in recent years. In addition, we are now investing up to £645 million across 2023/24 and 2024/25 in Pharmacy First, for more blood pressure checks and more contraception consultations in pharmacy. We have begun the consultation with Community Pharmacy England on the national funding and contractual framework arrangements for 2024/25.</p> answering member constituency South Northamptonshire answering member printed Andrea Leadsom question first answered 18/04/2024 16:00:23 answering member 4117 label Biography information for Andrea Leadsom
tabling member	4008 label Biography information for Dame Caroline Dinenage

1699970

registered interest
date	12/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pharmacy: Finance
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether she plans to increase the scope of the Pharmacy First programme.
tabling member constituency	Gosport
tabling member printed	Dame Caroline Dinenage
uin	20990
answer	answer is ministerial correction date of answer 18/04/2024 answer text <p>Pharmacy First was launched on 31 January 2024, and as the service embeds, we will monitor and evaluate the service, and keep the conditions covered by Pharmacy First under review.</p> answering member constituency South Northamptonshire answering member printed Andrea Leadsom question first answered 18/04/2024 16:57:21 answering member 4117 label Biography information for Andrea Leadsom
tabling member	4008 label Biography information for Dame Caroline Dinenage

1699971

registered interest
date	12/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Equipment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether she plans to develop a Priority Review programme for medical devices.
tabling member constituency	Gosport
tabling member printed	Dame Caroline Dinenage
uin	20991
answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The Priority Review programme is not currently planned, but the Government is taking other significant steps for medical device regulatory reform, as part of a broader Medical Technology Strategy. Further information on the Medical Technology Strategy is available at the following link:</p><p> </p><p><a href="https://www.gov.uk/government/publications/medical-technology-strategy/medical-technology-strategy" target="_blank">https://www.gov.uk/government/publications/medical-technology-strategy/medical-technology-strategy</a></p><p> </p><p>The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for regulating medical devices, and designates United Kingdom Approved Bodies to conduct conformity assessments against the relevant regulatory requirements. The MHRA works closely with Approved Bodies to ensure their timely assessment.</p><p> </p><p>Following a consultation on the future regulation of medical devices in 2021, the MHRA is leading a programme of work to introduce updated regulations for medical devices that prioritise patient safety, improve patient access to innovative medical devices, and ensure the UK remains an attractive market for medical technology innovators. In January of this year, the MHRA published a MedTech Regulatory roadmap that sets out the main activities in implementing the future regulations throughout 2024 and 2025. An international recognition framework for medical devices will form part of the future regulatory framework, which will provide an alternative route to the UK’s market, by leveraging approvals from comparable international regulators. The MHRA aims to publish an outline of the International Recognition Framework for medical devices later this spring, aligned to the Life Sciences Council, subject to necessary approvals.</p><p>In addition, the MHRA is leading the reform of the medical devices regulatory landscape and includes a new pathway to accelerate access to safe, innovative medical devices to help meet the unmet needs of patients. The Innovative Devices Access Pathway aims to bring new medical technologies and solutions to the National Health Service, to support the medical needs that are not currently being met. There are eight innovative medical technologies included in the pilot phase.</p><p>We are working alongside others to further the Life Sciences Vision, particularly improving regulation and regulatory processes around medical devices, and supporting broader ambitions in the vision aligned to the conditions set out in the Major Conditions Strategy. As we work to update the medical devices regulatory landscape, the MHRA is taking the Major Conditions Strategy into consideration, including the six groups of major health conditions.</p><p>The National Institute for Health and Care Excellence (NICE) is not a regulator but makes recommendations for the NHS on whether selected medical devices should be routinely adopted by the NHS, based on an assessment of their costs and benefits. Medical devices are prioritised for the NICE’s evaluation, in line with NICE’s published topic selection manual.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20992 20993 question first answered 22/04/2024 11:22:39 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4008 label Biography information for Dame Caroline Dinenage

1699972

registered interest
date	12/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Equipment: Reviews
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the Answer of 23 June 2023 to Question 189729 on Medicines and Healthcare products Regulatory Agency, whether she plans to initiate a priority review for medical devices.
tabling member constituency	Gosport
tabling member printed	Dame Caroline Dinenage
uin	20992
answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The Priority Review programme is not currently planned, but the Government is taking other significant steps for medical device regulatory reform, as part of a broader Medical Technology Strategy. Further information on the Medical Technology Strategy is available at the following link:</p><p> </p><p><a href="https://www.gov.uk/government/publications/medical-technology-strategy/medical-technology-strategy" target="_blank">https://www.gov.uk/government/publications/medical-technology-strategy/medical-technology-strategy</a></p><p> </p><p>The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for regulating medical devices, and designates United Kingdom Approved Bodies to conduct conformity assessments against the relevant regulatory requirements. The MHRA works closely with Approved Bodies to ensure their timely assessment.</p><p> </p><p>Following a consultation on the future regulation of medical devices in 2021, the MHRA is leading a programme of work to introduce updated regulations for medical devices that prioritise patient safety, improve patient access to innovative medical devices, and ensure the UK remains an attractive market for medical technology innovators. In January of this year, the MHRA published a MedTech Regulatory roadmap that sets out the main activities in implementing the future regulations throughout 2024 and 2025. An international recognition framework for medical devices will form part of the future regulatory framework, which will provide an alternative route to the UK’s market, by leveraging approvals from comparable international regulators. The MHRA aims to publish an outline of the International Recognition Framework for medical devices later this spring, aligned to the Life Sciences Council, subject to necessary approvals.</p><p>In addition, the MHRA is leading the reform of the medical devices regulatory landscape and includes a new pathway to accelerate access to safe, innovative medical devices to help meet the unmet needs of patients. The Innovative Devices Access Pathway aims to bring new medical technologies and solutions to the National Health Service, to support the medical needs that are not currently being met. There are eight innovative medical technologies included in the pilot phase.</p><p>We are working alongside others to further the Life Sciences Vision, particularly improving regulation and regulatory processes around medical devices, and supporting broader ambitions in the vision aligned to the conditions set out in the Major Conditions Strategy. As we work to update the medical devices regulatory landscape, the MHRA is taking the Major Conditions Strategy into consideration, including the six groups of major health conditions.</p><p>The National Institute for Health and Care Excellence (NICE) is not a regulator but makes recommendations for the NHS on whether selected medical devices should be routinely adopted by the NHS, based on an assessment of their costs and benefits. Medical devices are prioritised for the NICE’s evaluation, in line with NICE’s published topic selection manual.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20991 20993 question first answered 22/04/2024 11:22:39 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4008 label Biography information for Dame Caroline Dinenage

1699973

registered interest
date	12/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Equipment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether (a) the Medicines and Healthcare products Regulatory Agency and (b) NICE will prioritise the regulatory timelines for medical devices that (i) respond to conditions outlined in the Major Conditions Strategy and (ii) where there is unmet need.
tabling member constituency	Gosport
tabling member printed	Dame Caroline Dinenage
uin	20993
answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The Priority Review programme is not currently planned, but the Government is taking other significant steps for medical device regulatory reform, as part of a broader Medical Technology Strategy. Further information on the Medical Technology Strategy is available at the following link:</p><p> </p><p><a href="https://www.gov.uk/government/publications/medical-technology-strategy/medical-technology-strategy" target="_blank">https://www.gov.uk/government/publications/medical-technology-strategy/medical-technology-strategy</a></p><p> </p><p>The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for regulating medical devices, and designates United Kingdom Approved Bodies to conduct conformity assessments against the relevant regulatory requirements. The MHRA works closely with Approved Bodies to ensure their timely assessment.</p><p> </p><p>Following a consultation on the future regulation of medical devices in 2021, the MHRA is leading a programme of work to introduce updated regulations for medical devices that prioritise patient safety, improve patient access to innovative medical devices, and ensure the UK remains an attractive market for medical technology innovators. In January of this year, the MHRA published a MedTech Regulatory roadmap that sets out the main activities in implementing the future regulations throughout 2024 and 2025. An international recognition framework for medical devices will form part of the future regulatory framework, which will provide an alternative route to the UK’s market, by leveraging approvals from comparable international regulators. The MHRA aims to publish an outline of the International Recognition Framework for medical devices later this spring, aligned to the Life Sciences Council, subject to necessary approvals.</p><p>In addition, the MHRA is leading the reform of the medical devices regulatory landscape and includes a new pathway to accelerate access to safe, innovative medical devices to help meet the unmet needs of patients. The Innovative Devices Access Pathway aims to bring new medical technologies and solutions to the National Health Service, to support the medical needs that are not currently being met. There are eight innovative medical technologies included in the pilot phase.</p><p>We are working alongside others to further the Life Sciences Vision, particularly improving regulation and regulatory processes around medical devices, and supporting broader ambitions in the vision aligned to the conditions set out in the Major Conditions Strategy. As we work to update the medical devices regulatory landscape, the MHRA is taking the Major Conditions Strategy into consideration, including the six groups of major health conditions.</p><p>The National Institute for Health and Care Excellence (NICE) is not a regulator but makes recommendations for the NHS on whether selected medical devices should be routinely adopted by the NHS, based on an assessment of their costs and benefits. Medical devices are prioritised for the NICE’s evaluation, in line with NICE’s published topic selection manual.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20991 20992 question first answered 22/04/2024 11:22:40 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4008 label Biography information for Dame Caroline Dinenage

1699978

registered interest
date	12/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diabetes: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment she has made of the potential impact of discontinuing funding for T1DE pilot schemes on the health and well-being of patients living with type 1 diabetes with disordered eating.
tabling member constituency	Knowsley
tabling member printed	Sir George Howarth
uin	20895
answer	answer is ministerial correction date of answer 18/04/2024 answer text <p>NHS England has provided funding for eight integrated care boards (ICBs) across the country to support the development and establishment of Type 1 Diabetes with Disordered Eating (T1DE) services in every National Health Service region. Funding has been provided on a pump prime basis, and the responsibility for the longer-term sustainable provision of care for these patients sits with the relevant integrated care system.</p><p>A nationally commissioned evaluation has shown the positive impact that the provision of T1DE services can have for patients, including reductions in HbA1c, which is linked to reduced rates of diabetes complications, and reduced rates of emergency admissions.</p><p>It’s the role of the ICBs to consider the health needs of their populations, in making decisions about the care that is provided. It is expected that ICB leads consider these evaluation findings alongside the risk to patient health and wellbeing of the discontinuation of service provision, as well as other local contextual factors in making decisions about the future provision of T1DE services.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 18/04/2024 12:53:21 answering member 4044 label Biography information for Andrew Stephenson
tabling member	481 label Biography information for Sir George Howarth

1700005

registered interest
date	12/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Health Services and Pharmacy: Easington
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what information her Department holds on the number of pharmacies that have closed in Easington since 2019; and if she will make an assessment of the potential impact of these closures on primary care services.
tabling member constituency	Easington
tabling member printed	Grahame Morris
uin	20977
answer	answer is ministerial correction date of answer 18/04/2024 answer text <p>There were 21 physical pharmacies on 31 December 2023 in Easington constituency. Between 31 December 2019 and 31 December 2023, two pharmacies closed in Easington constituency. However, access remains good. 85 percent of the population in Easington live within a 20-minute walk from a pharmacy. This exceeds the national average of 80 percent. Residents of Easington can also access services from distance selling pharmacies that operate nationally.</p><p>It is the statutory duty of local authorities in England to undertake pharmaceutical needs assessments for their areas, every three years, to ensure provision continues to meet their population’s needs. Integrated care boards have regard to those assessments when commissioning services and where a pharmacy closure impacts on the access to services, a new contractor can apply to open a pharmacy in the area.</p> answering member constituency South Northamptonshire answering member printed Andrea Leadsom grouped question UIN 20978 question first answered 18/04/2024 15:42:30 answering member 4117 label Biography information for Andrea Leadsom
tabling member	3973 label Biography information for Grahame Morris

1700006

registered interest
date	12/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pharmacy: Closures
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment she has made of the potential impact of the closure of community pharmacies on the communities.
tabling member constituency	Easington
tabling member printed	Grahame Morris
uin	20978
answer	answer is ministerial correction date of answer 18/04/2024 answer text <p>There were 21 physical pharmacies on 31 December 2023 in Easington constituency. Between 31 December 2019 and 31 December 2023, two pharmacies closed in Easington constituency. However, access remains good. 85 percent of the population in Easington live within a 20-minute walk from a pharmacy. This exceeds the national average of 80 percent. Residents of Easington can also access services from distance selling pharmacies that operate nationally.</p><p>It is the statutory duty of local authorities in England to undertake pharmaceutical needs assessments for their areas, every three years, to ensure provision continues to meet their population’s needs. Integrated care boards have regard to those assessments when commissioning services and where a pharmacy closure impacts on the access to services, a new contractor can apply to open a pharmacy in the area.</p> answering member constituency South Northamptonshire answering member printed Andrea Leadsom grouped question UIN 20977 question first answered 18/04/2024 15:42:30 answering member 4117 label Biography information for Andrea Leadsom
tabling member	3973 label Biography information for Grahame Morris

1700007

registered interest
date	12/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pharmacy: Finance
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment she has made of the adequacy of the medication reimbursement mechanism for community pharmacists.
tabling member constituency	Easington
tabling member printed	Grahame Morris
uin	20979
answer	answer is ministerial correction date of answer 19/04/2024 answer text <p>Through the medicine margin survey, the Department assesses whether the reimbursement arrangements pay pharmacy contractors as agreed as part of the community pharmacy contractual framework (CPCF). The medicine margin survey considers what pharmacies paid for medicines by looking at their invoices compared to the amount reimbursed by the National Health Service. Where the survey finds that they have been underpaid, we increase the pharmacy contractors’ payments, and where they have been overpaid, we decrease payments.</p><p>Furthermore, where pharmacies cannot purchase products at or below the Drug Tariff NHS reimbursement price, Community Pharmacy England can request that the Department reassesses the reimbursement price. If a new reimbursement price is issued, this is known as a concessionary price.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20988 question first answered 19/04/2024 09:54:35 answering member 4044 label Biography information for Andrew Stephenson
tabling member	3973 label Biography information for Grahame Morris